Share Price and Basic Stock Data
Last Updated: January 21, 2026, 7:55 pm
| PEG Ratio | 10.18 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Fischer Medical Ventures Ltd operates in the Chemicals – Inorganic – Others industry, with a current market capitalization of ₹2,534 Cr. The company reported sales of ₹21 lakh for the year ending March 2024, a significant increase from ₹0 in the previous year. By March 2025, sales rose to ₹111 lakh, contributing to a trailing twelve months (TTM) revenue of ₹171 lakh. The quarterly sales exhibit a fluctuating trend, with the highest quarterly sales recorded at ₹86 lakh in September 2025. This growth trajectory indicates a rebound from initial stagnation, suggesting a potential turnaround in operational performance. However, the absence of sales in the initial quarters of FY 2023 raises concerns about the company’s revenue generation capabilities during that period. Overall, while the sales trend shows improvement, the historical context highlights the volatility in revenue generation.
Profitability and Efficiency Metrics
Fischer Medical Ventures reported a net profit of ₹1 lakh for the year ending March 2025, down from ₹2 lakh in March 2024, indicating challenges in maintaining profitability. The net profit margin stood at 1.53% for March 2025, a decline from 8.75% in the previous year, reflecting increased operational pressures. Operating profit margins (OPM) also declined significantly, recorded at 3% for FY 2025, down from 9% in FY 2024. The company’s cash conversion cycle (CCC) improved to 205 days in March 2025 from 398 days in March 2024, indicating enhanced efficiency in managing working capital. However, the return on equity (ROE) was a modest 0.35%, and return on capital employed (ROCE) was at 0.90%, both of which are below typical sector benchmarks. This suggests that while Fischer Medical Ventures is making strides in operational efficiency, it still faces significant challenges in profitability and returns.
Balance Sheet Strength and Financial Ratios
The balance sheet of Fischer Medical Ventures reflects a total asset value of ₹468 Cr as of September 2025, with total liabilities standing at ₹468 Cr, indicating a balanced structure. The company has reported reserves of ₹295 Cr, which is a positive sign of retained earnings and potential future investments. Borrowings have been managed at ₹30 Cr, demonstrating a conservative approach to leverage. The interest coverage ratio (ICR) stood at 9.80x, showcasing the company’s ability to meet interest obligations comfortably. However, the price-to-book value (P/BV) ratio at 16.97x suggests that the stock may be overvalued compared to its book value, which was ₹52.90 per share as of March 2025. Overall, while the company maintains a strong balance sheet with manageable debt levels, its high valuation ratios could pose a risk to investors.
Shareholding Pattern and Investor Confidence
Fischer Medical Ventures’ shareholding pattern indicates a significant shift in ownership dynamics. Promoter holdings were recorded at 61.80% as of September 2025, down from a peak of 74.91% in June 2024, suggesting a gradual dilution of promoter control. Foreign institutional investors (FIIs) have increased their stake to 5.57%, while domestic institutional investors (DIIs) hold a modest 1.42%. The public shareholding stands at 31.22%, reflecting a diversified ownership base. The number of shareholders increased to 13,054, indicating growing interest in the company. However, the declining promoter stake could raise concerns about long-term commitment, which may affect investor confidence. Overall, while the increasing number of shareholders points to potential market interest, the dilution of promoter holdings may warrant closer scrutiny.
Outlook, Risks, and Final Insight
The outlook for Fischer Medical Ventures appears cautiously optimistic, given the recent improvements in sales and operational efficiency. However, the company faces several risks, including fluctuating profitability and high valuation ratios which could deter potential investors. The declining net profit margin and return metrics suggest that while revenues are increasing, the company struggles to convert sales into profit effectively. Additionally, the high cash conversion cycle, although improved, indicates lingering inefficiencies in working capital management. Should Fischer Medical Ventures successfully enhance its profitability and maintain a balanced approach to growth, it could unlock significant value for shareholders. Conversely, failure to address these operational challenges may inhibit its ability to capitalize on market opportunities, underscoring the need for strategic focus moving forward.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Fischer Medical Ventures Ltd | 2,337 Cr. | 35.8 | 125/35.5 | 116 | 5.55 | 0.01 % | 1.08 % | 0.70 % | 1.00 |
| Emmessar Biotech & Nutrition Ltd | 13.7 Cr. | 27.4 | 42.9/25.8 | 59.6 | 16.0 | 0.00 % | 12.6 % | 4.23 % | 10.0 |
| Cochin Minerals & Rutile Ltd | 196 Cr. | 250 | 356/238 | 11.7 | 211 | 3.20 % | 23.3 % | 15.0 % | 10.0 |
| Archean Chemical Industries Ltd | 6,634 Cr. | 534 | 728/408 | 32.4 | 157 | 0.56 % | 16.0 % | 12.0 % | 2.00 |
| Alufluoride Ltd | 308 Cr. | 394 | 503/376 | 15.0 | 144 | 0.76 % | 23.6 % | 20.8 % | 10.0 |
| Industry Average | 4,636.00 Cr | 368.50 | 141.43 | 156.25 | 0.53% | 13.95% | 10.65% | 6.18 |
Quarterly Result
| Metric | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 21 | 10 | 40 | 12 | 49 | 23 | 86 |
| Expenses | 0 | 18 | 10 | 39 | 11 | 47 | 19 | 70 |
| Operating Profit | 0 | 3 | -0 | 0 | 0 | 2 | 4 | 16 |
| OPM % | 12% | -2% | 1% | 3% | 5% | 18% | 19% | |
| Other Income | 0 | 0 | 1 | 0 | 0 | 0 | 7 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 3 | 0 | 0 | 0 | 2 | 10 | 17 |
| Tax % | 6% | 271% | -38% | 350% | 28% | 51% | 19% | |
| Net Profit | 0 | 3 | -0 | 0 | -0 | 1 | 5 | 14 |
| EPS in Rs | 0.00 | 0.05 | -0.00 | 0.01 | -0.01 | 0.02 | 0.08 | 0.21 |
Last Updated: December 26, 2025, 11:38 pm
Below is a detailed analysis of the quarterly data for Fischer Medical Ventures Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 86.00 Cr.. The value appears strong and on an upward trend. It has increased from 23.00 Cr. (Jun 2025) to 86.00 Cr., marking an increase of 63.00 Cr..
- For Expenses, as of Sep 2025, the value is 70.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 19.00 Cr. (Jun 2025) to 70.00 Cr., marking an increase of 51.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 16.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Jun 2025) to 16.00 Cr., marking an increase of 12.00 Cr..
- For OPM %, as of Sep 2025, the value is 19.00%. The value appears strong and on an upward trend. It has increased from 18.00% (Jun 2025) to 19.00%, marking an increase of 1.00%.
- For Other Income, as of Sep 2025, the value is 2.00 Cr.. The value appears to be declining and may need further review. It has decreased from 7.00 Cr. (Jun 2025) to 2.00 Cr., marking a decrease of 5.00 Cr..
- For Interest, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 1.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 17.00 Cr.. The value appears strong and on an upward trend. It has increased from 10.00 Cr. (Jun 2025) to 17.00 Cr., marking an increase of 7.00 Cr..
- For Tax %, as of Sep 2025, the value is 19.00%. The value appears to be improving (decreasing) as expected. It has decreased from 51.00% (Jun 2025) to 19.00%, marking a decrease of 32.00%.
- For Net Profit, as of Sep 2025, the value is 14.00 Cr.. The value appears strong and on an upward trend. It has increased from 5.00 Cr. (Jun 2025) to 14.00 Cr., marking an increase of 9.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 0.21. The value appears strong and on an upward trend. It has increased from 0.08 (Jun 2025) to 0.21, marking an increase of 0.13.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:44 am
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|
| Sales | 0 | 21 | 111 | 171 |
| Expenses | 0 | 19 | 108 | 147 |
| Operating Profit | 0 | 2 | 3 | 23 |
| OPM % | 11% | 9% | 3% | 14% |
| Other Income | -0 | 0 | 1 | 10 |
| Interest | 0 | 0 | 0 | 2 |
| Depreciation | -0 | 0 | 2 | 2 |
| Profit before tax | -0 | 2 | 2 | 29 |
| Tax % | 13% | 45% | ||
| Net Profit | -0 | 2 | 1 | 20 |
| EPS in Rs | -0.24 | 0.03 | 0.02 | 0.30 |
| Dividend Payout % | -0% | -0% | 22% |
YoY Net Profit Growth
| Year | 2024-2025 |
|---|---|
| YoY Net Profit Growth (%) | -50.00% |
| Change in YoY Net Profit Growth (%) | 0.00% |
Fischer Medical Ventures Ltd has shown a consistent positive trend in YoY Net Profit Growth (%) in the last 1 years from 2024-2025 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 428% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -20% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 78% |
| 5 Years: | 91% |
| 3 Years: | 149% |
| 1 Year: | 79% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 1% |
Last Updated: September 5, 2025, 3:30 pm
Balance Sheet
Last Updated: December 4, 2025, 2:52 am
| Month | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|
| Equity Capital | 0.17 | 54 | 64 | 65 |
| Reserves | -0 | 28 | 274 | 295 |
| Borrowings | 1 | 2 | 85 | 30 |
| Other Liabilities | 0 | 4 | 34 | 77 |
| Total Liabilities | 0 | 86 | 457 | 468 |
| Fixed Assets | 0 | 15 | 24 | 31 |
| CWIP | 0 | 0 | 1 | 2 |
| Investments | 0 | 1 | 11 | 121 |
| Other Assets | 0 | 70 | 421 | 313 |
| Total Assets | 0 | 86 | 457 | 468 |
Below is a detailed analysis of the balance sheet data for Fischer Medical Ventures Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 65.00 Cr.. The value appears strong and on an upward trend. It has increased from 64.00 Cr. (Mar 2025) to 65.00 Cr., marking an increase of 1.00 Cr..
- For Reserves, as of Sep 2025, the value is 295.00 Cr.. The value appears strong and on an upward trend. It has increased from 274.00 Cr. (Mar 2025) to 295.00 Cr., marking an increase of 21.00 Cr..
- For Borrowings, as of Sep 2025, the value is 30.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 85.00 Cr. (Mar 2025) to 30.00 Cr., marking a decrease of 55.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 77.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 34.00 Cr. (Mar 2025) to 77.00 Cr., marking an increase of 43.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 468.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 457.00 Cr. (Mar 2025) to 468.00 Cr., marking an increase of 11.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 31.00 Cr.. The value appears strong and on an upward trend. It has increased from 24.00 Cr. (Mar 2025) to 31.00 Cr., marking an increase of 7.00 Cr..
- For CWIP, as of Sep 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Mar 2025) to 2.00 Cr., marking an increase of 1.00 Cr..
- For Investments, as of Sep 2025, the value is 121.00 Cr.. The value appears strong and on an upward trend. It has increased from 11.00 Cr. (Mar 2025) to 121.00 Cr., marking an increase of 110.00 Cr..
- For Other Assets, as of Sep 2025, the value is 313.00 Cr.. The value appears to be declining and may need further review. It has decreased from 421.00 Cr. (Mar 2025) to 313.00 Cr., marking a decrease of 108.00 Cr..
- For Total Assets, as of Sep 2025, the value is 468.00 Cr.. The value appears strong and on an upward trend. It has increased from 457.00 Cr. (Mar 2025) to 468.00 Cr., marking an increase of 11.00 Cr..
Notably, the Reserves (295.00 Cr.) exceed the Borrowings (30.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
Free Cash Flow
| Month | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Free Cash Flow | -1.00 | 0.00 | -82.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Debtor Days | 345 | 398 | 251 |
| Inventory Days | 36 | ||
| Days Payable | 82 | ||
| Cash Conversion Cycle | 345 | 398 | 205 |
| Working Capital Days | 324 | 498 | 107 |
| ROCE % | 5% | 1% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.08 | 1.65 | -2.12 |
| Diluted EPS (Rs.) | 0.08 | 1.08 | -2.12 |
| Cash EPS (Rs.) | 0.52 | 0.37 | -2.12 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 52.90 | 15.16 | -15.47 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 52.90 | 15.16 | -15.47 |
| Revenue From Operations / Share (Rs.) | 17.35 | 3.92 | 10.44 |
| PBDIT / Share (Rs.) | 0.75 | 0.44 | 0.88 |
| PBIT / Share (Rs.) | 0.50 | 0.40 | 0.88 |
| PBT / Share (Rs.) | 0.42 | 0.39 | -0.07 |
| Net Profit / Share (Rs.) | 0.26 | 0.34 | -2.12 |
| NP After MI And SOA / Share (Rs.) | 0.18 | 0.34 | -2.12 |
| PBDIT Margin (%) | 4.36 | 11.25 | 8.46 |
| PBIT Margin (%) | 2.89 | 10.38 | 8.46 |
| PBT Margin (%) | 2.44 | 10.06 | -0.72 |
| Net Profit Margin (%) | 1.53 | 8.75 | -20.33 |
| NP After MI And SOA Margin (%) | 1.09 | 8.75 | -20.33 |
| Return on Networth / Equity (%) | 0.35 | 2.26 | 0.00 |
| Return on Capital Employeed (%) | 0.90 | 2.64 | 4.97 |
| Return On Assets (%) | 0.26 | 2.12 | -10.32 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | -2.15 |
| Total Debt / Equity (X) | 0.17 | 0.00 | -2.15 |
| Asset Turnover Ratio (%) | 0.40 | 0.48 | 0.00 |
| Current Ratio (X) | 3.59 | 18.37 | 5.18 |
| Quick Ratio (X) | 3.50 | 17.20 | 5.18 |
| Inventory Turnover Ratio (X) | 16.23 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 9.80 | 34.92 | 0.92 |
| Interest Coverage Ratio (Post Tax) (X) | 4.43 | 28.19 | -1.21 |
| Enterprise Value (Cr.) | 5536.85 | 3303.93 | 1.98 |
| EV / Net Operating Revenue (X) | 50.02 | 157.47 | 11.03 |
| EV / EBITDA (X) | 1145.02 | 1399.44 | 130.31 |
| MarketCap / Net Operating Revenue (X) | 51.74 | 159.28 | 8.05 |
| Price / BV (X) | 16.97 | 41.20 | -5.43 |
| Price / Net Operating Revenue (X) | 51.74 | 159.31 | 8.05 |
| EarningsYield | 0.00 | 0.00 | -0.02 |
After reviewing the key financial ratios for Fischer Medical Ventures Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.08. This value is below the healthy minimum of 5. It has decreased from 1.65 (Mar 24) to 0.08, marking a decrease of 1.57.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.08. This value is below the healthy minimum of 5. It has decreased from 1.08 (Mar 24) to 0.08, marking a decrease of 1.00.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.52. This value is below the healthy minimum of 3. It has increased from 0.37 (Mar 24) to 0.52, marking an increase of 0.15.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 52.90. It has increased from 15.16 (Mar 24) to 52.90, marking an increase of 37.74.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 52.90. It has increased from 15.16 (Mar 24) to 52.90, marking an increase of 37.74.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 17.35. It has increased from 3.92 (Mar 24) to 17.35, marking an increase of 13.43.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 2. It has increased from 0.44 (Mar 24) to 0.75, marking an increase of 0.31.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.50. This value is within the healthy range. It has increased from 0.40 (Mar 24) to 0.50, marking an increase of 0.10.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.42. This value is within the healthy range. It has increased from 0.39 (Mar 24) to 0.42, marking an increase of 0.03.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.26. This value is below the healthy minimum of 2. It has decreased from 0.34 (Mar 24) to 0.26, marking a decrease of 0.08.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.18. This value is below the healthy minimum of 2. It has decreased from 0.34 (Mar 24) to 0.18, marking a decrease of 0.16.
- For PBDIT Margin (%), as of Mar 25, the value is 4.36. This value is below the healthy minimum of 10. It has decreased from 11.25 (Mar 24) to 4.36, marking a decrease of 6.89.
- For PBIT Margin (%), as of Mar 25, the value is 2.89. This value is below the healthy minimum of 10. It has decreased from 10.38 (Mar 24) to 2.89, marking a decrease of 7.49.
- For PBT Margin (%), as of Mar 25, the value is 2.44. This value is below the healthy minimum of 10. It has decreased from 10.06 (Mar 24) to 2.44, marking a decrease of 7.62.
- For Net Profit Margin (%), as of Mar 25, the value is 1.53. This value is below the healthy minimum of 5. It has decreased from 8.75 (Mar 24) to 1.53, marking a decrease of 7.22.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 8. It has decreased from 8.75 (Mar 24) to 1.09, marking a decrease of 7.66.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.35. This value is below the healthy minimum of 15. It has decreased from 2.26 (Mar 24) to 0.35, marking a decrease of 1.91.
- For Return on Capital Employeed (%), as of Mar 25, the value is 0.90. This value is below the healthy minimum of 10. It has decreased from 2.64 (Mar 24) to 0.90, marking a decrease of 1.74.
- For Return On Assets (%), as of Mar 25, the value is 0.26. This value is below the healthy minimum of 5. It has decreased from 2.12 (Mar 24) to 0.26, marking a decrease of 1.86.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.17. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.17, marking an increase of 0.17.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.40. It has decreased from 0.48 (Mar 24) to 0.40, marking a decrease of 0.08.
- For Current Ratio (X), as of Mar 25, the value is 3.59. This value exceeds the healthy maximum of 3. It has decreased from 18.37 (Mar 24) to 3.59, marking a decrease of 14.78.
- For Quick Ratio (X), as of Mar 25, the value is 3.50. This value exceeds the healthy maximum of 2. It has decreased from 17.20 (Mar 24) to 3.50, marking a decrease of 13.70.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 16.23. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 16.23, marking an increase of 16.23.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 9.80. This value is within the healthy range. It has decreased from 34.92 (Mar 24) to 9.80, marking a decrease of 25.12.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.43. This value is within the healthy range. It has decreased from 28.19 (Mar 24) to 4.43, marking a decrease of 23.76.
- For Enterprise Value (Cr.), as of Mar 25, the value is 5,536.85. It has increased from 3,303.93 (Mar 24) to 5,536.85, marking an increase of 2,232.92.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 50.02. This value exceeds the healthy maximum of 3. It has decreased from 157.47 (Mar 24) to 50.02, marking a decrease of 107.45.
- For EV / EBITDA (X), as of Mar 25, the value is 1,145.02. This value exceeds the healthy maximum of 15. It has decreased from 1,399.44 (Mar 24) to 1,145.02, marking a decrease of 254.42.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 51.74. This value exceeds the healthy maximum of 3. It has decreased from 159.28 (Mar 24) to 51.74, marking a decrease of 107.54.
- For Price / BV (X), as of Mar 25, the value is 16.97. This value exceeds the healthy maximum of 3. It has decreased from 41.20 (Mar 24) to 16.97, marking a decrease of 24.23.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 51.74. This value exceeds the healthy maximum of 3. It has decreased from 159.31 (Mar 24) to 51.74, marking a decrease of 107.57.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fischer Medical Ventures Ltd:
- Net Profit Margin: 1.53%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 0.9% (Industry Average ROCE: 13.95%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.35% (Industry Average ROE: 10.65%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.43
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.5
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 116 (Industry average Stock P/E: 141.43)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.17
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 1.53%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Equipment & Accessories | Survey No. 480/2 AP Medtech Zone, Nadupura Village, Vishakapatnam Andhra Pradesh 530032 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ravindran Govindan | Chairman & Managing Director |
| Ms. Svetlana Rao | Whole Time Executive Director |
| Mr. Sanjay Jayantilal Jain | Independent Director |
| Mr. Jaya Ankur Singhania | Independent Director |
| Mr. Khairy Jamaluddin Abu Bakkar | Independent Director |
| Mr. Roberto M Pagdanganan | Independent Director |
FAQ
What is the intrinsic value of Fischer Medical Ventures Ltd?
Fischer Medical Ventures Ltd's intrinsic value (as of 21 January 2026) is ₹4.02 which is 88.77% lower the current market price of ₹35.80, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹2,337 Cr. market cap, FY2025-2026 high/low of ₹125/35.5, reserves of ₹295 Cr, and liabilities of ₹468 Cr.
What is the Market Cap of Fischer Medical Ventures Ltd?
The Market Cap of Fischer Medical Ventures Ltd is 2,337 Cr..
What is the current Stock Price of Fischer Medical Ventures Ltd as on 21 January 2026?
The current stock price of Fischer Medical Ventures Ltd as on 21 January 2026 is ₹35.8.
What is the High / Low of Fischer Medical Ventures Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Fischer Medical Ventures Ltd stocks is ₹125/35.5.
What is the Stock P/E of Fischer Medical Ventures Ltd?
The Stock P/E of Fischer Medical Ventures Ltd is 116.
What is the Book Value of Fischer Medical Ventures Ltd?
The Book Value of Fischer Medical Ventures Ltd is 5.55.
What is the Dividend Yield of Fischer Medical Ventures Ltd?
The Dividend Yield of Fischer Medical Ventures Ltd is 0.01 %.
What is the ROCE of Fischer Medical Ventures Ltd?
The ROCE of Fischer Medical Ventures Ltd is 1.08 %.
What is the ROE of Fischer Medical Ventures Ltd?
The ROE of Fischer Medical Ventures Ltd is 0.70 %.
What is the Face Value of Fischer Medical Ventures Ltd?
The Face Value of Fischer Medical Ventures Ltd is 1.00.